Quarterly ResultAug 6, 2026, 07:11 AM
Iovance Biotherapeutics Q2 Revenue $99.3M; Net Loss $(0.11) EPS
AI Summary
Iovance Biotherapeutics reported record second quarter 2026 financial results, with total product revenue reaching ~$99.3 million, a 66% increase year-over-year. The company achieved a gross margin of 56% and significantly reduced its net loss to $(47.3) million, or $(0.11) per share. Due to strong performance, Iovance is reviewing its full-year 2026 revenue guidance and announced key clinical and regulatory advancements, including FDA Fast Track Designation for Lifileucel in soft tissue sarcomas and Amtagvi approval in Australia.
Key Highlights
- Total product revenue for Q2 2026 was ~$99.3 million, a 66% increase year-over-year.
- U.S. Amtagvi revenue reached ~$91 million, up 40% from Q4 2025.
- Gross margin increased to 56% in Q2 2026.
- Net Loss for Q2 2026 was $(47.3) million, or $(0.11) per share.
- FDA granted Fast Track Designation for Lifileucel in Soft Tissue Sarcomas.
- Company is reviewing its FY26 total revenue guidance of $350 million to $370 million.
- Cash, cash equivalents, and investments totaled ~$304 million as of June 30, 2026.
- Amtagvi marketing authorization application approved by TGA in Australia.
Price Impact
More from IOVA